ZAI LAB LIMITED Increase (Decrease) in Accounts Receivable
ZAI LAB LIMITED (ZLAB) reported Increase (Decrease) in Accounts Receivable of -$39.03 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-08-06
- ZAI LAB LIMITED increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was $14.24M, a 21.87% increase year-over-year.
- ZAI LAB LIMITED increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was -$53.27M.
- ZAI LAB LIMITED increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was $19.66M, a 46.42% decline year-over-year.
- ZAI LAB LIMITED increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was -$3.67M.
- ZAI LAB LIMITED increase (decrease) in accounts receivable for fiscal 2025 was $18.93M, a 29.82% decline from fiscal 2024.
- ZAI LAB LIMITED increase (decrease) in accounts receivable for fiscal 2024 was $26.98M, a 34.61% increase from fiscal 2023.
- ZAI LAB LIMITED increase (decrease) in accounts receivable for fiscal 2023 was $20.04M.
- ZAI LAB LIMITED increase (decrease) in accounts receivable for fiscal 2022 was -$4.33M, a 110.23% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month | Increase (Decrease) in Accounts Receivable 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $14.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$39.03M 10-Q · filed 2026-08-06 | -$19.37M derived: sum of 3 quarters · filed 2026-08-06 | -$23.04M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | -$53.27M 10-Q · filed 2026-05-07 | -$33.61M derived: sum of 2 quarters · filed 2026-05-07 | -$37.28M derived: sum of 3 quarters · filed 2026-05-07 | -$25.60M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | $19.66M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $15.99M derived: sum of 2 quarters · filed 2026-02-26 | $27.67M derived: sum of 3 quarters · filed 2026-08-06 | $18.93M 10-K · filed 2026-02-26 | |
| 2025-09-30 | -$3.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $8.01M derived: sum of 2 quarters · filed 2026-08-06 | -$726.00K 10-Q · filed 2025-11-06 | $35.96M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | $11.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $2.94M 10-Q · filed 2026-08-06 | $39.63M derived: sum of 3 quarters · filed 2026-08-06 | $19.08M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | -$8.74M 10-Q · filed 2026-05-07 | $27.95M derived: sum of 2 quarters · filed 2026-05-07 | $7.40M derived: sum of 3 quarters · filed 2026-05-07 | $16.91M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | $36.69M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $16.13M derived: sum of 2 quarters · filed 2026-02-26 | $25.65M derived: sum of 3 quarters · filed 2026-02-26 | $26.98M 10-K · filed 2026-02-26 | |
| 2024-09-30 | -$20.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$11.04M derived: sum of 2 quarters · filed 2025-11-06 | -$9.71M 10-Q · filed 2025-11-06 | $7.50M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-06-30 | $9.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $10.84M 10-Q · filed 2025-08-07 | $28.06M derived: sum of 3 quarters · filed 2026-02-26 | $22.02M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-03-31 | $1.33M 10-Q · filed 2025-05-08 | $18.55M derived: sum of 2 quarters · filed 2026-02-26 | $12.51M derived: sum of 3 quarters · filed 2026-02-26 | $18.52M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2023-12-31 | $17.22M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $11.18M derived: sum of 2 quarters · filed 2026-02-26 | $17.19M derived: sum of 3 quarters · filed 2026-02-26 | $20.04M 10-K · filed 2026-02-26 | |
| 2023-09-30 | -$6.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$29.00K derived: sum of 2 quarters · filed 2024-11-12 | $2.82M 10-Q · filed 2024-11-12 | $14.98M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-06-30 | $6.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $8.86M 10-Q · filed 2024-08-06 | $21.02M derived: sum of 3 quarters · filed 2025-02-27 | $24.95M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-03-31 | $2.85M 10-Q · filed 2024-05-08 | $15.01M derived: sum of 2 quarters · filed 2025-02-27 | $18.94M derived: sum of 3 quarters · filed 2025-02-27 | $12.60M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2022-12-31 | $12.15M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $16.09M derived: sum of 2 quarters · filed 2025-02-27 | $9.75M derived: sum of 3 quarters · filed 2025-02-27 | -$4.33M 10-K · filed 2025-02-27 | |
| 2022-09-30 | $3.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$2.40M derived: sum of 2 quarters · filed 2023-11-07 | -$16.48M 10-Q · filed 2023-11-07 | $9.98M derived: sum of 4 quarters · filed 2024-02-27 | |
| 2022-06-30 | -$6.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | -$20.42M 10-Q · filed 2023-08-07 | $6.04M derived: sum of 3 quarters · filed 2024-02-27 | $9.03M derived: sum of 4 quarters · filed 2024-02-27 | |
| 2022-03-31 | -$14.08M 10-Q · filed 2023-05-09 | $12.38M derived: sum of 2 quarters · filed 2024-02-27 | $15.37M derived: sum of 3 quarters · filed 2024-02-27 | $24.59M derived: sum of 4 quarters · filed 2024-02-27 | |
| 2021-12-31 | $26.46M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $29.45M derived: sum of 2 quarters · filed 2024-02-27 | $38.67M derived: sum of 3 quarters · filed 2024-02-27 | $42.32M 10-K · filed 2024-02-27 | |
| 2021-09-30 | $2.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $12.21M derived: sum of 2 quarters · filed 2022-11-09 | $15.86M 10-Q · filed 2022-11-09 | $13.53M derived: sum of 4 quarters · filed 2023-03-01 | |
| 2021-06-30 | $9.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $12.87M 10-Q · filed 2022-08-09 | $10.54M derived: sum of 3 quarters · filed 2023-03-01 | $11.01M derived: sum of 4 quarters · filed 2023-03-01 | |
| 2021-03-31 | $3.65M 10-Q · filed 2022-05-10 | $1.32M derived: sum of 2 quarters · filed 2023-03-01 | $1.79M derived: sum of 3 quarters · filed 2023-03-01 | $4.73M derived: sum of 4 quarters · filed 2023-03-01 | |
| 2020-12-31 | -$2.33M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | -$1.86M derived: sum of 2 quarters · filed 2023-03-01 | $1.08M derived: sum of 3 quarters · filed 2023-03-01 | $1.38M 10-K · filed 2023-03-01 | |
| 2020-09-30 | $469.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $3.41M derived: sum of 2 quarters · filed 2021-11-09 | $3.70M 10-Q · filed 2021-11-09 | ||
| 2020-06-30 | $2.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $3.23M 10-Q · filed 2021-08-09 | |||
| 2020-03-31 | $296.00K 10-Q · filed 2021-05-10 | ||||
| 2019-12-31 | $3.70M 10-K · filed 2022-03-01 | ||||
| 2019-06-30 | $2.39M 6-K · filed 2020-09-11 | ||||
| 2018-12-31 | $90.00K 10-K · filed 2021-03-01 | $89.71K 20-F · filed 2019-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |